XBRANE Stock Overview
A biotechnology company, engages in the development, manufacture, and sale of biosimilars.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Xbrane Biopharma AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.18 |
52 Week High | SEK 73.70 |
52 Week Low | SEK 0.17 |
Beta | 1.17 |
11 Month Change | -34.44% |
3 Month Change | -13.02% |
1 Year Change | -99.76% |
33 Year Change | -99.88% |
5 Year Change | -99.41% |
Change since IPO | -99.50% |
Recent News & Updates
Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower
Aug 05Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost
Jun 21Recent updates
Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower
Aug 05Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost
Jun 21Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?
Jun 04We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully
Nov 05Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)
Mar 24Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings
Mar 02Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price
Feb 10We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth
Jan 12What Kind Of Investors Own Most Of Xbrane Biopharma AB (publ) (STO:XBRANE)?
Dec 16Insider Buying: The Xbrane Biopharma AB (publ) (STO:XBRANE) Head of Manufacturing & Supply Chain Just Bought 50% More Shares
Nov 20Shareholder Returns
XBRANE | SE Biotechs | SE Market | |
---|---|---|---|
7D | -30.5% | -2.4% | -4.3% |
1Y | -99.8% | 18.0% | 12.6% |
Return vs Industry: XBRANE underperformed the Swedish Biotechs industry which returned 18.1% over the past year.
Return vs Market: XBRANE underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
XBRANE volatility | |
---|---|
XBRANE Average Weekly Movement | 16.6% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: XBRANE's share price has been volatile over the past 3 months.
Volatility Over Time: XBRANE's weekly volatility has decreased from 30% to 17% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 75 | Martin Amark | www.xbrane.com |
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma.
Xbrane Biopharma AB (publ) Fundamentals Summary
XBRANE fundamental statistics | |
---|---|
Market cap | SEK 270.72m |
Earnings (TTM) | -SEK 361.27m |
Revenue (TTM) | SEK 190.97m |
1.4x
P/S Ratio-0.7x
P/E RatioIs XBRANE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XBRANE income statement (TTM) | |
---|---|
Revenue | SEK 190.97m |
Cost of Revenue | SEK 161.51m |
Gross Profit | SEK 29.46m |
Other Expenses | SEK 390.73m |
Earnings | -SEK 361.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | -0.24 |
Gross Margin | 15.43% |
Net Profit Margin | -189.18% |
Debt/Equity Ratio | 45.3% |
How did XBRANE perform over the long term?
See historical performance and comparison